Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?

References

• Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940–954.
   PubMed Web of Science ®Google Scholar
• Ivanova D, Gaudon C, Rossin A. RAR–RXR selectivity and biological activity of new retinoic acid analogues with heterocyclic or polycyclic aromatic systems. Bioorg Med Chem. 2002;10:2099–2102.
   PubMed Web of Science ®Google Scholar
• Petkovich M, Brand NJ, Krust A, et al. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 1987;330:444–450.
   PubMed Web of Science ®Google Scholar
• Hanley K, Jiang Y, He SS, et al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol. 1998;110:368–375.
   PubMed Web of Science ®Google Scholar
• Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364–1371.
   PubMed Web of Science ®Google Scholar
• Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett. 1991;57:223–227.
   PubMed Web of Science ®Google Scholar
• Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53:358–588.
   PubMed Web of Science ®Google Scholar
• Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol. 1992;3:513–526.
   PubMed Web of Science ®Google Scholar
• Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 2002;100:1399–1403.
   PubMed Web of Science ®Google Scholar
• Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of retinoids. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. New York: Raven Press, 1994. p. 443–520.
   Google Scholar
• Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Assoc. 1997;96:525–534.
   PubMed Web of Science ®Google Scholar
• Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res. 1998;22:611–618.
   PubMed Web of Science ®Google Scholar
• Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia. 2002;16:1896–1905.
   PubMed Web of Science ®Google Scholar
• Tang X-H, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345–364.
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572.
   PubMed Web of Science ®Google Scholar
• Kessler JF, Meyskens FL Jr, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983;1:1345–1347.
   PubMed Web of Science ®Google Scholar
• Warrell RP, Jr, Coonley CJ, Kempin SJ, et al. Isotretinoin in cutaneous T-cell lymphoma. Lancet. 1983;2:629
   PubMed Web of Science ®Google Scholar
• Thomsen K, Molin L, Volden G, et al. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1984;64:563–566.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JE, Mellette JR. Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol. 1986;12:626–629.
   PubMedGoogle Scholar
• Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol. 1987;123:201–204.
   PubMed Web of Science ®Google Scholar
• Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987;67:232–236.
   PubMed Web of Science ®Google Scholar
• Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987;147:529–531.
   PubMed Web of Science ®Google Scholar
• Leverkus M, Rose C, Bröcker EB, et al. Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol. 2005;152:193–194.
   PubMed Web of Science ®Google Scholar
• Molin S, Ruzicka T. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic–rhagadiform skin changes and mycosis fungoides or Sézary syndrome. Br J Dermatol. 2009;161:1420–1422.
   PubMed Web of Science ®Google Scholar
• Cheeley J, Sahn RE, DeLong LK, et al. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68:247–254.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Hodgkin’s Lymphomas, Version 3, 2018. http://www.NCCN.org
   Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi149–vi154.
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Kim Y, et al. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581–593.
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II–III trial results. J Clin Oncol. 2001;19:2456–2471.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598–2607.
   PubMed Web of Science ®Google Scholar
• Hodak E, Amitay-Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement. J Am Acad Dermatol. 2014;70:993–1001.
   PubMed Web of Science ®Google Scholar
• Hodak E, Amitay-Laish I, Atzmony L, et al. New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol. 2016;75:347–355.
   PubMed Web of Science ®Google Scholar
• van Santen S, Roach RE, van Doorn R, et al. Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol. 2016;152:992–1000.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004;51:25–32.
   PubMed Web of Science ®Google Scholar
• Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18:655–662.
   PubMed Web of Science ®Google Scholar
• Berbis P, Geiger JM, Vaisse C, et al. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis. Dermatologica. 1989;178:88–92.
   PubMedGoogle Scholar
• Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol. 2013;27:e305–e311.
   PubMed Web of Science ®Google Scholar
• Wang L, DeMarco SS, Peaks MS, et al. RARα/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines. Exp Dermatol. 2017;26:1004–1011.
   PubMed Web of Science ®Google Scholar
• Miernik B, Schmidt V, Technau-Hafsi K, et al. Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach. Clin Exp Dermatol. 2015;40:445–447.
   PubMed Web of Science ®Google Scholar
• Kapser C, Herzinger T, Ruzicka T, et al. Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol. 2015;29:783–788.
   PubMed Web of Science ®Google Scholar
• Schmitz L, Bierhoff E, Dirschka T. Alitretinoin: an effective treatment option for pagetoid reticulosis. J Dtsch Dermatol Ges. 2013;11:1194–1195.
   PubMed Web of Science ®Google Scholar
• Coors EA, von den Driesch P. Treatment of 2 patients with mycosis fungoides with alitretinoin. J Am Acad Dermatol. 2012;67:e265–e267.
   PubMed Web of Science ®Google Scholar
• Park J, Kwon O, Park K, et al. Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation. Clin Exp Dermatol. 2017;42:341–342.
   PubMed Web of Science ®Google Scholar
• Sokołowska-Wojdyło M, Ługowska-Umer H, Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol. 2013;1:19–29.
   Google Scholar
• Heller EH, Shiffman NJ. Synthetic retinoids in dermatology. Can Med Assoc J. 1985;132:1129–1136.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Su IJ, Chen CC, et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J Clin Oncol. 1994;12:1185–1192.
   PubMed Web of Science ®Google Scholar
• Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002;8:1234–1240.
   PubMed Web of Science ®Google Scholar
• Rook AH, Kubin M, Fox FE, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann NY Acad Sci. 1996;795:310–318.
   PubMed Web of Science ®Google Scholar
• Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Aust J Dermatol. 2010;51:248–253.
   PubMed Web of Science ®Google Scholar
• Arican O, Sasmaz S, Ozbulut O. Increased suicidal tendency in a case of Psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venerol. 2006;20:464–465.
   PubMed Web of Science ®Google Scholar